{"id":"https://openalex.org/W4361952181","doi":"https://doi.org/10.1158/1078-0432.c.6523112","title":"Data from Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma","display_name":"Data from Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361952181","doi":"https://doi.org/10.1158/1078-0432.c.6523112"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6523112","doi":"https://doi.org/10.1158/1078-0432.c.6523112","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6523112","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.c.6523112","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029872582","display_name":"Raffit Hassan","orcid":"https://orcid.org/0000-0002-4012-3633","observed_orcids":["https://orcid.org/0000-0002-4012-3633"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Raffit Hassan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090156519","display_name":"Hedy Lee Kindler","orcid":"https://orcid.org/0000-0002-5450-842X","observed_orcids":["https://orcid.org/0000-0002-5450-842X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hedy L. Kindler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110482662","display_name":"Thierry Marie Jahan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thierry Jahan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036466135","display_name":"Lyudmila A. Bazhenova","orcid":"https://orcid.org/0000-0001-8764-4359","observed_orcids":["https://orcid.org/0000-0001-8764-4359"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lyudmila Bazhenova","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046728958","display_name":"Martin Reck","orcid":"https://orcid.org/0000-0002-5348-4462","observed_orcids":["https://orcid.org/0000-0002-5348-4462"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martin Reck","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074644543","display_name":"Anish Thomas","orcid":"https://orcid.org/0000-0003-3293-3115","observed_orcids":["https://orcid.org/0000-0003-3293-3115"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anish Thomas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056573254","display_name":"Ira H Pastan","orcid":"https://orcid.org/0000-0002-9223-0270","observed_orcids":["https://orcid.org/0000-0002-9223-0270"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ira Pastan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110727162","display_name":"Jeff Parno","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeff Parno","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110575402","display_name":"Daniel John O'Shannessy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel J. O'Shannessy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027537503","display_name":"Penny Fatato","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Penny Fatato","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110198789","display_name":"Julia D. Maltzman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julia D. Maltzman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"Bruce A. Wallin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruce A. Wallin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11026","display_name":"Occupational and environmental lung diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11026","display_name":"Occupational and environmental lung diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12064","display_name":"Intraperitoneal and Appendiceal Malignancies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11356","display_name":"Pleural and Pulmonary Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mesothelin","display_name":"mesothelin","score":0.8759999871253967},{"id":"https://openalex.org/keywords/malignant-pleural-mesothelioma","display_name":"malignant pleural mesothelioma","score":0.8920000195503235},{"id":"https://openalex.org/keywords/pemetrexed","display_name":"pemetrexed","score":0.8880000114440918},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":1.0},{"id":"https://openalex.org/keywords/chimeric-monoclonal-antibody","display_name":"chimeric monoclonal antibody","score":0.9309999942779541},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5559999942779541},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8980000019073486},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9860000014305115},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.7289999723434448},{"id":"https://openalex.org/keywords/hypersensitivity","display_name":"hypersensitivity","score":0.6290000081062317}],"concepts":[{"id":"https://openalex.org/C2777240266","wikidata":"https://www.wikidata.org/wiki/Q415220","display_name":"Pemetrexed","level":4,"score":0.894719660282135},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7789491415023804},{"id":"https://openalex.org/C2777407522","wikidata":"https://www.wikidata.org/wiki/Q1077603","display_name":"Mesothelioma","level":2,"score":0.6691577434539795},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6010761857032776},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.5525734424591064},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5373291969299316},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4995396137237549},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.47605153918266296},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4706273078918457},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.43929323554039},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3658882975578308},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3140649199485779},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.14422166347503662}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.c.6523112","doi":"https://doi.org/10.1158/1078-0432.c.6523112","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6523112","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.c.6523112.v1","doi":"https://doi.org/10.1158/1078-0432.c.6523112.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6523112.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6523112","doi":"https://doi.org/10.1158/1078-0432.c.6523112","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6523112","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2150869832","https://openalex.org/W2600984772","https://openalex.org/W3000592816","https://openalex.org/W2891238215","https://openalex.org/W3021245509","https://openalex.org/W2801311742","https://openalex.org/W2898395149","https://openalex.org/W3000510324","https://openalex.org/W2892243610","https://openalex.org/W3209332662"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"Amatuximab":[2,204],"is":[3],"a":[4,10,51,242],"chimeric":[5],"monoclonal":[6],"antibody":[7],"to":[8,82,250],"mesothelin,":[9],"cell":[11],"surface":[12],"glycoprotein":[13],"highly":[14],"expressed":[15],"in":[16,29,43,145,160,166],"malignant":[17],"pleural":[18],"mesothelioma":[19],"(MPM).":[20],"On":[21],"the":[22,34,235,254],"basis":[23],"of":[24,37,77,125,130,220,244,256],"its":[25],"synergy":[26],"with":[27,45,66,86,196,205,212,241],"chemotherapy":[28],"preclinical":[30],"studies,":[31],"we":[32],"evaluated":[33],"antitumor":[35],"activity":[36],"amatuximab":[38,56,92,140,252],"plus":[39],"pemetrexed":[40,67,206],"and":[41,64,70,114,135,163,187,207,247],"cisplatin":[42,71,208],"patients":[44,118,138,150,198,245],"unresectable":[46],"MPM.":[47],"Experimental":[48],"Design:":[49],"In":[50],"single-arm":[52],"phase":[53],"II":[54],"study,":[55],"(5":[57],"mg/kg)":[58],"was":[59,99,133,172,181,190,209,228,238],"administered":[60],"on":[61,74],"days":[62],"1":[63,76],"8":[65],"(500":[68],"mg/m2)":[69,73],"(75":[72],"day":[75],"21-day":[78],"cycles":[79,127],"for":[80],"up":[81],"six":[83],"cycles.":[84],"Patients":[85],"response":[87,112,215],"or":[88,216],"stable":[89,164,217],"disease":[90,95,165,218],"received":[91,139],"maintenance":[93],"until":[94],"progression.":[96],"Primary":[97],"endpoint":[98],"progression-free":[100],"survival":[101,110],"(PFS)":[102],"at":[103,121,200,253],"6":[104],"months.":[105],"Secondary":[106],"endpoints":[107],"were":[108,119],"overall":[109],"(OS),":[111],"rate,":[113],"safety.":[115],"Results:":[116],"Eighty-nine":[117],"enrolled":[120],"26":[122],"centers.":[123],"Median":[124],"five":[126],"(range,":[128],"1\u20136)":[129],"combination":[131],"treatment":[132],"administered,":[134],"56":[136],"(63%)":[137],"maintenance.":[141],"Combination":[142],"therapy":[143],"resulted":[144],"no":[146],"overlapping":[147],"toxicities.":[148],"Eleven":[149],"(12.4%)":[151],"had":[152],"amatuximab-related":[153],"hypersensitivity":[154],"reactions.":[155],"Responses":[156],"included":[157],"partial":[158],"responses":[159],"33":[161],"(40%)":[162],"42":[167],"(51%).":[168],"Six-month":[169],"PFS":[170,180,227],"rate":[171,219],"51%":[173],"[95%":[174],"confidence":[175],"interval":[176],"(CI),":[177],"39.1\u201362.3)],":[178],"median":[179,188,236],"6.1":[182],"months":[183,192,240],"(95%":[184,193],"CI,":[185,194],"5.8\u20136.4),":[186],"OS":[189,237],"14.8":[191,239],"12.4\u201318.5)":[195],"29":[197],"alive":[199,246],"data":[201],"cut-off.":[202],"Conclusions:":[203],"well":[210],"tolerated":[211],"objective":[213],"tumor":[214],"90%":[221],"by":[222],"independent":[223],"radiologic":[224],"review.":[225],"Although":[226],"not":[229],"significantly":[230],"different":[231],"from":[232],"historical":[233],"controls,":[234],"third":[243],"5":[248],"continuing":[249],"receive":[251],"time":[255],"analysis.":[257],"Clin":[258],"Cancer":[259],"Res;":[260],"20(23);":[261],"5927\u201336.":[262],"\u00a92014":[263],"AACR.":[264]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}